Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
Abstract Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including the most detailed analysis of BAP1 alterations to date. We identified histology-independent molecular prognostic subsets, and defined a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity. We also report strong expression of the immune-checkpoint gene VISTA in epithelioid MPM, strikingly higher than in other solid cancers, with implications for the immune response to MPM and for its immunotherapy. Our findings highlight new avenues for further investigation of MPM biology and novel therapeutic options. Significance: Through a comprehensive integrated genomic study of 74 MPMs, we provide a deeper understanding of histology-independent determinants of aggressive behavior, define a novel genomic subtype with TP53 and SETDB1 mutations and extensive loss of heterozygosity, and discovered strong expression of the immune-checkpoint gene VISTA in epithelioid MPM. See related commentary by Aggarwal and Albelda, p. 1508. This article is highlighted in the In This Issue feature, p. 1494
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a study that explored 74 mesothelioma tumors using a genomic analysis identified TGF-β1 mRNA expression as being correlated with the worst patient prognoses [40].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053
Self-citationThe Life History of 21 Breast Cancers
Nik-Zainal, S., Van Loo, P., Wedge, D. C., Alexandrov, L. B., Greenman, C. D., Lau, K. W., Raine, K., Jones, D., Marshall, J., Ramakrishna, M., et al. (2012) · Cell · doi:10.1016/j.cell.2012.04.023 · Cited by 1,443 · cited 1×
“Since MPM with evidence of GNH have typically undergone a genome-doubling event, we were able to assess the timing of this relative to point mutations (30,31).”
BackgroundSelf-citationSomatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396 · cited 1×
“This places MPM at the low end of somatic mutation burden among cancers (8).”
BackgroundSelf-citationShen, R., & Seshan, V. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw520 · Cited by 1,258
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Clock-like mutational processes in human somatic cells
Alexandrov, L. B., Jones, P. H., Wedge, D. C., Sale, J. E., Campbell, P. J., Nik-Zainal, S., & Stratton, M. R. (2015) · Nature Genetics · doi:10.1038/ng.3441 · Cited by 1,058
Self-citationBueno, R., Stawiski, E. W., Goldstein, L. D., Durinck, S., De Rienzo, A., Modrusan, Z., Gnad, F., Nguyen, T. T., Jaiswal, B. S., Chirieac, L. R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3520 · Cited by 919
Self-citationShen, R., Olshen, A. B., & Ladanyi, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp543 · Cited by 849 · cited 1×
“To find out whether multi-platform molecular profiling might provide additional resolution to define prognostic subsets of MPM, we performed integrative clustering across multiple assay platforms using two algorithms: iCluster (32) and PARADIGM (33).”
MethodSelf-citationVaske, C. J., Benz, S. C., Sanborn, J. Z., Earl, D., Szeto, C., Zhu, J., Haussler, D., & Stuart, J. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq182 · Cited by 786
Self-citationThe genomic landscape of hypodiploid acute lymphoblastic leukemia
Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.-C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2532 · Cited by 731
Self-citationBott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
Self-citationVISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688 · cited 4×
“Mavrakis KJ, McDonald ER, 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.”
BackgroundInfluentialSelf-citationComprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma
Zheng, S., Cherniack, A. D., Dewal, N., Moffitt, R. A., Danilova, L., Murray, B. A., Lerario, A. M., Else, T., Knijnenburg, T. A., Ciriello, G., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.002 · Cited by 657 · cited 1×
“, acute lymphoblastic leukemia, chondrosarcoma, and adrenocortical carcinoma), the strong association of TP53 and SETDB1 comutation with widespread LOH has not been previously reported in other cancers (28, 29).”
BackgroundSelf-citationDisordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., et al. (2016) · Science · doi:10.1126/science.aad5944 · Cited by 607 · cited 4×
“Mavrakis KJ, McDonald ER, 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5.”
BackgroundInfluentialGao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Self-citationShen, R., Olshen, A. B., & Ladanyi, M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp659 · Cited by 566
Self-citationMak, M. P., Tong, P., Diao, L., Cardnell, R. J., Gibbons, D. L., William, W. N., Skoulidis, F., Parra, E. R., Rodriguez-Canales, J., Wistuba, I. I., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0876 · Cited by 535
Self-citationAlley, E. W., Lopez, J., Santoro, A., Morosky, A., Saraf, S., Piperdi, B., & van Brummelen, E. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30169-9 · Cited by 490
Loss of BAP1 function leads to EZH2-dependent transformation
LaFave, L. M., Béguelin, W., Koche, R., Teater, M., Spitzer, B., Chramiec, A., Papalexi, E., Keller, M. D., Hricik, T., Konstantinoff, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3947 · Cited by 381
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
Self-citationHigh Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma
Nasu, M., Emi, M., Pastorino, S., Tanji, M., Powers, A., Luk, H., Baumann, F., Zhang, Y.-A., Gazdar, A., Kanodia, S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000471 · Cited by 326
Self-citationNovel Insights into Mesothelioma Biology and Implications for Therapy
Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.42 · Cited by 324
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Carbone, M., Ferris, L. K., Baumann, F., Napolitano, A., Lum, C. A., Flores, E. G., Gaudino, G., Powers, A., Bryant-Greenwood, P., Krausz, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-179 · Cited by 323
Self-citationGuo, G., Chmielecki, J., Goparaju, C., Heguy, A., Dolgalev, I., Carbone, M., Seepo, S., Meyerson, M., & Pass, H. I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1008 · Cited by 321
Self-citationGanly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
Flies, D. B., Han, X., Higuchi, T., Zheng, L., Sun, J., Ye, J. J., & Chen, L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74589 · Cited by 282
Molecular pathogenesis of malignant mesothelioma
Sekido, Y. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt166 · Cited by 279
Self-citationYu, H., Mashtalir, N., Daou, S., Hammond-Martel, I., Ross, J., Sui, G., Hart, G. W., Rauscher, F. J., Drobetsky, E., Milot, E., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00396-10 · Cited by 270
Self-citationLópez-Ríos, F., Chuai, S., Flores, R., Shimizu, S., Ohno, T., Wakahara, K., Illei, P. B., Hussain, S., Krug, L., Zakowski, M. F., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3907 · Cited by 245
Self-citationVISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236 · cited 3×
“clinical trials of emerging anti-VISTA therapy (42,44) (NCT02812875) in epithelioid MPM.”
BackgroundResultImmunoregulatory functions of VISTA
Nowak, E. C., Lines, J. L., Varn, F. S., Deng, J., Sarde, A., Mabaera, R., Kuta, A., Le Mercier, I., Cheng, C., & Noelle, R. J. (2017) · Immunological Reviews · doi:10.1111/imr.12525 · Cited by 197
Epithelial–mesenchymal transition in malignant mesothelioma
Fassina, A., Cappellesso, R., Guzzardo, V., Via, L. D., Piccolo, S., Ventura, L., & Fassan, M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.144 · Cited by 156
de Reyniès, A., Jaurand, M.-C., Renier, A., Couchy, G., Hysi, I., Elarouci, N., Galateau-Sallé, F., Copin, M.-C., Hofman, P., Cazes, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2429 · Cited by 148
Self-citationIdentification of ALK Rearrangements in Malignant Peritoneal Mesothelioma
Hung, Y. P., Dong, F., Watkins, J. C., Nardi, V., Bueno, R., Cin, P. D., Godleski, J. J., Crum, C. P., & Chirieac, L. R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2918 · Cited by 139
Self-citationDesmeules, P., Joubert, P., Zhang, L., Al‐Ahmadie, H. A., Fletcher, C. D. �., Vakiani, E., DeLair, D. F., Rekhtman, N., Ladanyi, M., Travis, W. D., et al. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000864 · Cited by 117
Self-citationPrognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas
Đačić, S., Kothmaier, H. E., Land, S. R., Shuai, Y., Halbwedl, I., Morbini, P., Murer, B., Comin, C., Galateau-Sallé, F., Demirağ, F., et al. (2008) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-008-0689-3 · Cited by 116
Self-citationMalignant mesothelioma as an oxidative stress-induced cancer: An update
Chew, S. H., & Toyokuni, S. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.002 · Cited by 102
GAS5 long non-coding RNA in malignant pleural mesothelioma
Renganathan, A., Kresoja‐Rakic, J., Echeverry, N., Ziltener, G., Vrugt, B., Opitz, I., Stahel, R. A., & Felley‐Bosco, E. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-119 · Cited by 100
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma
Williams, M., Kirschner, M. B., Cheng, Y. Y., Hanh, J., Weiss, J., Amaro-Mugridge, N. B., Wright, C. M., Linton, A., Kao, S., Edelman, J. J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4346 · Cited by 90
Self-citationKeniry, A., Gearing, L. J., Jansz, N., Liu, J. J., Holik, A. Z., Hickey, P. F., Kinkel, S., Moore, D., Breslin, K. A., Chen, K., et al. (2016) · Epigenetics & Chromatin · doi:10.1186/s13072-016-0064-6 · Cited by 88
Self-citationOu, S. I., Moon, J., Garland, L. L., Mack, P. C., Testa, J. R., Tsao, A. S., Wozniak, A. J., & Gandara, D. R. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000360 · Cited by 80
Self-citationRNA sequencing identifies fusion of theEWSR1andYY1genes in mesothelioma with t(14;22)(q32;q12)
Panagopoulos, I., Thorsen, J., Gorunova, L., Micci, F., Haugom, L., Davidson, B., & Heim, S. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22068 · Cited by 77
Suraokar, M. B., Nunez, M. I., Diao, L., Chow, C., Kim, D., Behrens, C., Lin, H., Lee, S., Raso, G., Moran, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu127 · Cited by 73
Self-citationLuchini, C., Veronese, N., Yachida, S., Cheng, L., Nottegar, A., Stubbs, B., Solmi, M., Capelli, P., Pea, A., Barbareschi, M., et al. (2016) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.22381 · Cited by 62
A New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
Kang, H. C., Kim, H. K., Lee, S., Mendez, P., Kim, J. W., Woodard, G., Yoon, J.-H., Jen, K.-Y., Fang, L. T., Jones, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7032 · Cited by 51
Self-citationScherpereel, A., Mazieres, J., Greillier, L., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba8507 · Cited by 50
A Proteomic Analysis of the Malignant Mesothelioma Secretome Using iTRAQ
Creaney, J., Dick, I. M., Leon, J. S., & Robinson, B. W. S. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20023 · Cited by 45
Self-citationLong Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM)
Wright, C. M., Kirschner, M. B., Cheng, Y. Y., O'Byrne, K. J., Gray, S. G., Schelch, K., Hoda, M. A., Klebe, S., McCaughan, B. C., van Zandwijk, N., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070940 · Cited by 44
Self-citationLeong, S. L., Zainudin, R., Kazan‐Allen, L., & Robinson, B. W. (2015) · Respirology · doi:10.1111/resp.12517 · Cited by 44
Self-citationOsmanbeyoglu, H. U., Toska, E., Chan, C., Baselga, J. M., & Leslie, C. S. (2017) · Nature Communications · doi:10.1038/ncomms14249 · Cited by 40
Self-citationTan, K., Kajino, K., Momose, S., Masaoka, A., Sasahara, K., Shiomi, K., Izumi, H., Abe, M., Ohtsuji, N., Wang, T., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.03.002 · Cited by 35
Hagenaars, M., Zwaveling, S., Kuppen, P. J. K., Ensink, N. G., Eggermont, A. M. M., Hokland, M., Basse, P. H., van de Velde, C. J. �., Fleuren, G. J., & Nannmark, U. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19981209)78:6<740::aid-ijc12>3.0.co;2-5 · Cited by 34
Shaw, T. J., Zhang, X. Y., Huo, Z., Robertson, D. M., Lovell, P. A., Dalgleish, A. G., & Barton, D. P. J. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000697 · Cited by 30
Antiproliferative effect of Aurora kinase targeting in mesothelioma
Crispi, S., Fagliarone, C., Biroccio, A., D’Angelo, C., Galati, R., Sacchi, A., Vincenzi, B., Baldi, A., & Verdina, A. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.03.005 · Cited by 22
Immunotherapy for Lung Malignancies
Chee, J., Robinson, B. W. S., Holt, R. A., & Creaney, J. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.10.007 · Cited by 21
Self-citationPolycomb recruitment at the Class II transactivator gene
Boyd, N., Morgan, J. E., & Greer, S. F. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.08.003 · Cited by 13
Maki, Y., Nishimura, Y., Toyooka, S., Soh, J., Tsukuda, K., Shien, K., Furukawa, M., Muraoka, T., Ueno, T., Tanaka, N., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4412 · Cited by 7
(2003) · PubMed
Self-citation
Cited by
Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
Self-citationIntercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling
Wu, J., Minikes, A. M., Gao, M., Bian, H., Li, Y., Stockwell, B. R., Chen, Z.-N., & Jiang, X. (2019) · Nature · doi:10.1038/s41586-019-1426-6 · Cited by 1,110
Schürch, C. M., Bhate, S. S., Barlow, G. L., Phillips, D. J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.005 · Cited by 1,064
Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine
Dey, A., Varelas, X., & Guan, K.-L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0070-z · Cited by 860
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Metadata
- Authors
- Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., Bowlby, R., Kanchi, R., Osmanbeyoglu, H. U., Sekido, Y., Takeshita, J., Newton, Y., Graim, K., Gupta, M., Gay, C. M., Diao, L., Gibbs, D. L., Thorsson, V., Iype, L., Kantheti, H., Severson, D. T., Ravegnini, G., Desmeules, P., Jungbluth, A. A., Travis, W. D., Dacic, S., Chirieac, L. R., Galateau-Sallé, F., Fujimoto, J., Husain, A. N., Silveira, H. C., Rusch, V. W., Rintoul, R. C., Pass, H., Kindler, H., Zauderer, M. G., Kwiatkowski, D. J., Bueno, R., Tsao, A. S., Creaney, J., Lichtenberg, T., Leraas, K., Bowen, J., TCGA Research Network, Felau, I., Zenklusen, J. C., Akbani, R., Cherniack, A. D., Byers, L. A., Noble, M. S., Fletcher, J. A., Robertson, A. G., Shen, R., Aburatani, H., Robinson, B. W., Campbell, P., Ladanyi, M., Aburatani, H., Akbani, R., Ally, A., Anur, P., Armenia, J., Auman, J. T., Balasundaram, M., Balu, S., Baylin, S. B., Becich, M., Behrens, C., Beroukhim, R., Bielski, C., Bodenheimer, T., Bootwalla, M. S., Bowen, J., Bowlby, R., Brooks, D., Bueno, R., Byers, L. A., Cárcano, F. M., Carlsen, R., Carvalho, A. L., Cherniack, A. D., Cheung, D., Chirieac, L., Cho, J., Chuah, E., Chudamani, S., Cibulskis, C., Cope, L., Crain, D., Creaney, J., Curley, E., Dacic, S., Danilova, L., Rienzo, A. D., DeFreitas, T., Demchok, J. A., Dhalla, N., Dhir, R., Diao, L., Drill, E., Felau, I., Feldman, M., Ferguson, M. L., Fletcher, J. A., Fujimoto, J., Fujimoto, J., Fukuda, S., Gabriel, S. B., Sallé, F. G., Gao, J., Gardner, J., Gastier-Foster, J. M., Gay, C. M., Gehlenborg, N., Gerken, M., Getz, G., Gibb, E. A., Gibbs, D. L., Goparaju, C., Graim, K., Gross, B., Guo, G., Gupta, M., Hasegawa, S., Haussler, D., Hayes, D. N., Heiman, D. I., Heins, Z., Hmeljak, J., Hoadley, K. A., Holt, R. A., Hoyle, A. P., Husain, A., Hutter, C. M., Iype, L., Jefferys, S. R., Jones, S. J. M., Jones, C. D., Kanchi, R. S., Kasaian, K., Kim, J., Kindler, H., Kondo, N., Krausz, T., Kundra, R., Kuribayashi, K., Kwiatkowski, D. J., Ladanyi, M., Lai, P. H., Laird, P. W., Lawrence, M. S., Lee, D., Leraas, K. M., Lichtenberg, T. M., Lin, P., Liu, J., Liu, W., Liu, E. M., Lolla, L., Longatto-Filho, A., Lu, Y., Luketich, J., Ma, Y., Maglinte, D. T., Mallory, D., Marra, M. A., Mayo, M., Meier, S., Melamed, J., Meng, S., Meyerson, M., Mieczkowski, P. A., Mills, G. B., Moore, R. A., Moran, C., Morris, S., Mose, L. E., Mungall, A. J., Mungall, K., Nakano, T., Naresh, R., Newton, Y., Noble, M. S., Ochoa, A., Osmanbeyoglu, H., Parker, J. S., Pass, H. I., Paulauskis, J., Pennathur, A., Pennell, N. A., Penny, R., Perou, C. M., Pihl, T., Ramirez, N. C., Rassl, D. M., Ravegnini, G., Reid, G., Reis, R. M., Reynolds, S. M., Rice, D., Richards, W. G., Rintoul, R. C., Roach, J., Robertson, A. G., Rusch, V., Sadeghi, S., Saksena, G., Sanchez-Vega, F., Sander, C., Sato, A., Scapulatempo-Neto, C., Schein, J. E., Schultz, N., Schumacher, S. E., Seiwert, T., Sekido, Y., Severson, D. T., Shelton, C., Shelton, T., Shen, R., Sheridan, R., Shi, Y., Shih, J., Shiraishi, Y., Shmulevich, I., Silveira, H. C. S., Simons, J. V., Sipahimalani, P., Skelly, T., Sofia, H. J., Soloway, M. G., Spellman, P., Stewart, C., Stuart, J., Sun, Q., Takeshita, J., Tam, A., Tan, D., Tarnuzzer, R., Tatsuno, K., Taylor, B. S., Thiessen, N., Thompson, E., Thorsson, V., Travis, W. D., Tsao, A., Tse, K., Tsujimura, T., Valdivieso, F., Van Den Berg, D. J., van Zandwijk, N., Veluvolu, U., Viana, L. S., Voet, D., Wan, Y., Wang, Z., Wang, J., Weaver, J., Weinstein, J. N., Weisenberger, D. J., Wilkerson, M. D., Wise, L., Wistuba, I., Wong, T., Wu, Y., Yamamoto, S., Yang, L., Zauderer, M. G., Zenklusen, J. C., Zhang, J., Zhang, H., Zhang, H., & Zmuda, E.
- Affiliations
- 3Department of Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Wellcome Sanger Institute (GB)
- 10Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 11Computational Systems Biology, Memorial Sloan Kettering Cancer Center, New York, New York.
- The University of Texas at Dallas (US)
- Institut universitaire de cardiologie et de pneumologie de Québec (CA)
- Memorial Sloan Kettering Cancer Center (US)
- 23Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
- 24MESOPATH. Cancer Center Leon Berard, Lyon, France.
- 26Department of Pathology, University of Chicago, Chicago, Illinois.
- 27Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Sao Paulo, Brazil.
- 28Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
- 30Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.
- 15Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 35The Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
- 36National Cancer Institute, Bethesda, Maryland.
- 18Division of Thoracic Surgery, The Lung Center and International Mesothelioma Program, Brigham and Women's Hospital, Boston, Massachusetts.
- The University of Western Australia (AU)
- ORCID
- Tarpey, Patrick
- Kantheti, Havish
- Desmeules, Patrice
- Jungbluth, Achim A.
- Silveira, Henrique C.
- Tsao, Anne S.
- Robinson, Bruce W.
- Campbell, Peter
- Armenia, Joshua
- Auman, J. Todd
- Baylin, Stephen B.
- Becich, Michael
- Behrens, Carmen
- Beroukhim, Rameen
- Bootwalla, Moiz S.
- Cibulskis, Carrie
- Cope, Leslie
- Rienzo, Assunta De
- Dhir, Rajiv
- Ferguson, Martin L.
- Fukuda, Shiro
- Gabriel, Stacey B.
- Gao, Jianjiong
- Gehlenborg, Nils
- Getz, Gad
- Goparaju, Chandra
- Gross, Benjamin
- Guo, Guangwu
- Hasegawa, Seiki
- Haussler, David
- Hayes, D. Neil
- Heins, Zachary
- Holt, Robert A.
- Hoyle, Alan P.
- Jefferys, Stuart R.
- Jones, Steven J.M.
- Jones, Corbin D.
- Kasaian, Katayoon
- Kim, Jaegil
- Kondo, Nobuyuki
- Kundra, Ritika
- Kuribayashi, Kozo
- Laird, Peter W.
- Lawrence, Michael S.
- Lee, Darlene
- Lin, Pei
- Liu, Jia
- Liu, Wenbin
- Liu, Eric Minwei
- Lu, Yiling
- Luketich, James
- Maglinte, Dennis T.
- Marra, Marco A.
- Mayo, Michael
- Melamed, Jonathan
- Meyerson, Matthew
- Mieczkowski, Piotr A.
- Mills, Gordon B.
- Mungall, Andrew J.
- Nakano, Takashi
- Ochoa, Angelica
- Parker, Joel S.
- Pennathur, Arjun
- Pennell, Nathan A.
- Perou, Charles M.
- Pihl, Todd
- Ramirez, Nilsa C.
- Rassl, Doris M.
- Reid, Glen
- Reis, Rui M.
- Rice, David
- Richards, William G
- Roach, Jeffrey
- Sadeghi, Sara
- Saksena, Gordon
- Sander, Chris
- Sato, Ayuko
- Schultz, Nikolaus
- Schumacher, Steven E.
- Seiwert, Tanguy
- Shi, Yan
- Shiraishi, Yuichi
- Sofia, Heidi J.
- Spellman, Paul
- Sun, Qiang
- Tam, Angela
- Tarnuzzer, Roy
- Tatsuno, Kenji
- Taylor, Barry S
- Tsujimura, Tohru
- Wang, Jing
- Weaver, Joellen
- Weinstein, John N.
- Weisenberger, Daniel J.
- Wilkerson, Matthew D.
- Wistuba, Ignacio
- Wong, Tina
- Wu, Ye
- Yamamoto, Shogo
- Yang, Liming
- Zhang, Jiashan
- Zhang, Hailei
- Zhang, Hongxin
- Zmuda, Erik
- Venue
- Cancer Discovery
- Published
- 2018-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 1548-1565
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6310008
- OpenAlex
- W2897299514
- Cited by
- 618
- References
- 62
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 61 · 2023: 78 · 2022: 96 · 2021: 117 · 2020: 100 · 2019: 45 · 2018: 4
- FWCI
- 50.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Funders
- HHS | National Institutes of Health (NIH) (U54 HG003273, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025, P30 CA016672, P30 CA008748, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848)
- British Lung Foundation (BLF) (APG11-7)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- malignant pleural mesothelioma, TP53 mutation, loss of heterozygosity, genomic subtypes, VISTA, immune checkpoint, epithelioid mesothelioma, immunotherapy, antitumor immunity
- MeSH terms
- Aged, Female, Humans, Lung Neoplasms, Male, Mesothelioma, Middle Aged, Mutation, Pleural Neoplasms, Prognosis, Histone-Lysine N-Methyltransferase, Protein Methyltransferases, Biomarkers, Tumor, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.